top of page


FDA declines approval of Summit and Akeso's ivonescimab for EGFR-mutated lung cancer
The FDA has issued a Complete Response Letter for Summit Therapeutics' ivonescimab in EGFR-mutated lung cancer after the HARMONi trial demonstrated a progression-free survival benefit but did not establish a statistically significant overall-survival benefit.

nuaxia
1 day ago2 min read


FDA Issues Complete Response Letter for Reproxalap in Dry Eye Disease
Aldeyra Therapeutics’ new drug application for reproxalap was not approved due to insufficient clinical trial data demonstrating efficacy.

nuaxia
Mar 181 min read
bottom of page